Samuel Kuykendall, MD
Urology · Kansas City, MONPI 1194948778
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $106,631 of the $140,614 with a category attached, or 75.8%. 32 manufacturers reported payments, led by AbbVie at 40.0% of the total. Reporting peaked in 2019 at $31,594 and has fallen 65.9% since, to $10,773 in 2025. Among urology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $393.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$56K
- Antares Pharma, Inc.$38K
- Sumitomo Pharma America, Inc.$26K
- Astellas Pharma US Inc$9K
- Coloplast$7K
- Axonics, Inc.$2K
- plus $3K from 26 others
What the payments were for
- Consulting fees$15,66011%
- Speaking & faculty fees$106,63176%
- Travel & lodging$6,6125%
- Food & beverage$6,3645%
- Education$5,3244%
- Gifts$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $56,196 |
| Antares Pharma, Inc. | 48 | $37,656 |
| Sumitomo Pharma America, Inc. | 20 | $25,927 |
| Astellas Pharma US Inc | 30 | $8,579 |
| Coloplast | 15 | $6,720 |
| Axonics, Inc. | 31 | $2,263 |
| Medtronic(2 entities) | 17 | $1,322 |
| Caldera Medical, Inc | 13 | $478 |
| Johnson & Johnson | 33 | $387 |
| Boston Scientific | 6 | $358 |
| Teleflex LLC | 1 | $168 |
| Rochester Medical Corporation | 3 | $87 |
| Dendreon Pharmaceuticals LLC | 2 | $52 |
| Agiliti Health, Inc. | 2 | $52 |
| Intuitive Surgical | 1 | $49 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Amgen | 2 | $31 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Urogen Pharma, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Mission Pharmacal Company | 1 | $18 |
| Olympus America Inc. | 1 | $16 |
| Blue Earth Diagnostics | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $15 |
| Tolmar, Inc. | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Convatec Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,614 in reported general payments places this provider in the 95th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 305 | $297,566 |
| MyrbetriqMirabegron | 194 | $164,754 |
| ElmironPentosan Polysulfate Sodium | 12 | $12,126 |
| Estradiol | 117 | $8,734 |
| Tamsulosin Hcl | 420 | $6,518 |
| Methenamine Hippurate | 94 | $4,091 |
| Solifenacin Succinate | 96 | $3,142 |
| Oxybutynin Chloride ErOxybutynin Chloride | 120 | $2,989 |
| Finasteride | 202 | $2,873 |
| Potassium Citrate ErPotassium Citrate | 38 | $2,720 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 23 | $2,551 |
| Desmopressin Acetate | 19 | $1,785 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $1,524 |
| Testosterone | 22 | $1,299 |
| Cefdinir | 21 | $1,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $25,927 | $297,566305 claims |
| Astellas Pharma US IncMyrbetriq | $8,579 | $164,754194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 urology providers in Missouri.
Other urology in Kansas City
- Donald NeffKansas City$27K
- Lukas HockmanKansas City$14K
- Patrick ProbstKansas City$14K
- Daniel HolmesKansas City$9K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.